Stock Events

GB Sciences 

$0.01
6
-$0-35% Friday 18:24

Statistics

Day High
0.01
Day Low
0.01
52W High
0.01
52W Low
0.01
Volume
4,597
Avg. Volume
69,406
Mkt Cap
4.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9NovExpected
Q3 2020
Q4 2020
Q2 2021
Q3 2021
Q4 2021
Q2 2022
Q3 2022
-0
0
0.01
0.01
Expected EPS
N/A
Actual EPS
-0.0009

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GBLX. It's not an investment recommendation.
Alphabet
75333
GOOGL
Apple
65621
AAPL
Microsoft
61102
MSFT
Amazon
56572
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Cronos Group
CRON
Mkt Cap863.96M
Cronos Group is involved in the production and sale of cannabis and cannabis-derived products, making it a competitor in the cannabis market space.
Tilray Brands
TLRY
Mkt Cap1.44B
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, competing with GB Sciences in the medicinal cannabis sector.
Canopy Growth
CGC
Mkt Cap580.69M
Canopy Growth Corporation is a diversified cannabis and cannabinoid-based consumer product company, competing across several of GB Sciences' target markets.
Aurora Cannabis
ACB
Mkt Cap332.34M
Aurora Cannabis is engaged in the production, distribution, and sale of cannabis products, directly competing with GB Sciences in the cannabis industry.
OrganiGram
OGI
Mkt Cap192.03M
OrganiGram Holdings is a producer of medical and recreational cannabis, competing with GB Sciences in both markets.
Curaleaf
CURLF
Mkt Cap2.15B
Curaleaf Holdings operates in the medical and recreational cannabis sectors, making it a direct competitor to GB Sciences in multiple aspects of the cannabis industry.

About

Biotechnology
Health Technology
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
Show more...
CEO
John Poss
Employees
3
Country
US
ISIN
US3615441090

Listings

US
GBLX